NEW USE

摘要

The present invention relates to methods and pharmaceutical compositions for the prevention or in delaying time to first occurrence of mortality, in particular cardiovascular death, and/or of cardiovascular hospitalizations in a patient suffering from chronic systolic heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug to said patient.

主权项

1. Use of
a) a therapeutically effective amount of the compound of the formula
[(A1)(A2)](Na)y.xH2O  (I)whereinA1 is S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in its anionic form;A2 is (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in its anionic form;Na is a sodium ion;y is 1 to 3; andx is 0 to 3; or b) a combination comprising a therapeutically effective amount of a 1:1 molar ratio of
(i) valsartan or a pharmaceutically acceptable salt thereof; and(ii) sacubitril or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention or delaying time to first occurrence of mortality and/or of cardiovascular hospitalizations in a patient suffering from chronic systolic heart failure.